Anaptysbio (ANAB) Total Current Liabilities (2016 - 2026)
Anaptysbio's (ANAB) quarterly Total Current Liabilities came in at $41.7 million in Q1 2026, down 5.3% YoY from $44.0 million in Q1 2025, and up 7.97% on a QoQ basis from $38.6 million in Q4 2025.
Anaptysbio (ANAB) Total Current Liabilities (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Total Current Liabilities data on file, last reported at $41.7 million in Q1 2026.
- Quarterly Total Current Liabilities fell 5.3% year-over-year to $41.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.7 million (down 5.3% YoY) and the FY2025 annual result came in at $38.6 million, down 14.98% from the prior year.
- Total Current Liabilities advanced to $41.7 million in Q1 2026, from $38.6 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $45.4 million in Q4 2024 to a low of $19.8 million in Q1 2022.
- A 5-year average of $35.3 million and a median of $38.1 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities surged 109.51% — and 2025, when it fell 14.98%.
- Tracing ANAB's Total Current Liabilities over 5 years: stood at $26.1 million in 2022, then surged by 43.71% to $37.4 million in 2023, then gained by 21.33% to $45.4 million in 2024, then slipped by 14.98% to $38.6 million in 2025, then grew by 7.97% to $41.7 million in 2026.
- The last three Total Current Liabilities figures came in at $41.7 million (Q1 2026), $38.6 million (Q4 2025), and $38.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 41.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.70 Mn |
| Dec 31, 2025 | 38.63 Mn |
| Sep 30, 2025 | 38.10 Mn |
| Jun 30, 2025 | 35.53 Mn |
| Mar 31, 2025 | 44.04 Mn |
| Dec 31, 2024 | 45.43 Mn |
| Sep 30, 2024 | 43.88 Mn |
| Jun 30, 2024 | 40.42 Mn |
| Mar 31, 2024 | 32.30 Mn |
| Dec 31, 2023 | 37.44 Mn |
| Sep 30, 2023 | 39.18 Mn |
| Jun 30, 2023 | 41.63 Mn |
| Mar 31, 2023 | 35.80 Mn |
| Dec 31, 2022 | 26.05 Mn |
| Sep 30, 2022 | 21.06 Mn |
| Jun 30, 2022 | 19.87 Mn |
| Mar 31, 2022 | 19.78 Mn |
| Dec 31, 2021 | 16.10 Mn |
| Sep 30, 2021 | 20.89 Mn |
| Jun 30, 2021 | 20.62 Mn |